Lenz & Staehelin advises Emergent on the sale of its travel vaccine business

Emergent BioSolutions, the New York Stock Exchange listed developer and manufacturer of vaccines, completed the sale of its travel vaccine business to Bavarian Nordic for an upfront payment of USD 270 million. At closing Emergent received the payment, subject to customary closing adjustments, and may receive up to an additional $110 million in potential future milestone payments.

With the transaction closed, Bavarian Nordic has acquired the rights to Vivotif®, the licensed typhoid vaccine, and Vaxchora®, the licensed cholera vaccine, as well as the development-stage chikungunya vaccine candidate CHIKV VLP. Bavarian also acquired manufacturing facilities in Bern, Switzerland, and development facilities in San Diego, California. The majority of Emergent employees supporting these products and facilities are joining Bavarian Nordic.

Lenz & Staehelin advised Emergent BioSolutions in this transaction. The team included Tino Gaberthüel (pictured left) and Simone Ehrsam (pictured right, both partners corporate and m&a), Fabiano Menghini (partner real estate), Stephanie Buschta (associate real estate), Anja Affolter Marino (associate employment) and Lukas Aebi (associate tax).